Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer

L. Thomas, Anne; Morgan, Bruno; A. Horsfield, Mark; Higginson, Anthony; Kay, Andrea; Lee, Lucy; Masson, Eric; Puccio-Pick, Marie; Laurent, Dirk; P. Steward, William

doi:10.1200/jco.2005.09.034

Public

Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer

Shared by NobleBlocks on Jun 20, 2005 • 12:00 AM UTC

Authors:

Anne L. Thomas

Bruno Morgan

Mark A. Horsfield

Abstract

Purpose PTK787/ZK 222584 (PTK/ZK) is an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor (VEGF) receptor tyrosine kinases, including VEGFR-1/Flt-1, VEGFR-2/KDR, VEGFR-3/Flt-4, the platelet-derived growth factor receptor tyrosine kinase, and the c-kit protein tyrosin...

Discussions